Kraft Heinz Co vs Tempus AI — how do they compare? Kraft Heinz Co trades at $22.19 (market cap $26.66B), while Tempus AI trades at $71.26 (market cap $12.58B). The key difference: Kraft Heinz Co is far larger — about 2.1× Tempus AI's market cap, and Kraft Heinz Co pays a 7.12% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Tempus AI for 23 Days on average.
| KHC | TEM | |
|---|---|---|
Market Cap | $26.66B | $12.58B |
Volume | 31,300,109 | 7,444,569 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $27.62 | $99.28 |
52-Week Low | $21.21 | $41.55 |
Typical Hold Time | 129 Days | 23 Days |
Enterprise Value | $42.98B | $13.21B |
Dividend Yield | 7.12% | — |
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.08, up 0.45% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with a low P/E of 13.04 and P/B of 0.74, but negative profitability metrics including a net income margin of -13.64% and ROE of -8.78% reflect challenges from a recent $5.85B net loss in 2025. The company maintains strong operating cash flow of $4.46B and a dividend yield near 6.5%, supported by ongoing brand reinvestment efforts.
The investment outlook is cautious; valuation discounts may attract value investors, but persistent volume declines and high debt pose significant risks. Analyst consensus is mixed with a $24.50 price target, yet only 11.43% recommend buying. Key catalysts include successful turnaround execution and new product launches, though competitive pressures and margin recovery remain critical hurdles for sustained shareholder value.
Tempus AI (TEM) trades at $71.46, up 1.66% with a bullish technical signal despite negative profitability metrics. The stock shows strong analyst support with 9 buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and 13 ESMO Congress presentations highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist at -$254M.
Outlook remains cautiously optimistic given strong institutional backing and AI healthcare growth potential, but profitability challenges and insider selling present near-term risks. The stock's valuation appears stretched with P/S of 8.61 and P/B of 28.27, requiring sustained revenue acceleration to justify current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →